Physician profile
Daniel B Hadzic
NPI 1548487929
$394.19
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.16 · 2020: $183 · 2021: $154.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $215.45 | 2020-2021 | |
| Abbvie INC. | $50.91 | 2019-2021 | |
| Allergan, INC. | $32.14 | 2020 | |
| Kci USA, INC. | $22.50 | 2019 | |
| Mylan Specialty L.P. | $16.51 | 2021 | |
| Tris Pharma INC | $15.93 | 2020 | |
| Pacira Therapeutics, INC. | $15.26 | 2020 | |
| Therapeuticsmd, INC. | $12.80 | 2020 | |
| Merck Sharp & Dohme LLC | $12.69 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hadzic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.